[Regulatory effect of Chinese herbal compound for detoxifying and activating blood circulation on expression of NF-kappaB and MMP-9 in aorta of apolipoprotein E gene knocked-out mice].
OBJECTIVE
To observe the regulatory effect of Chinese herbal compound for detoxifying and activating blood circulation on expression of nuclear factor-kappaB (NF-kappaB) and matrix metalloproteinase-9 (MMP-9) in aorta of apolipoprotein E gene knocked-out (ApoE (-/-)) mice.


METHODS
ApoE (-/-) mice of 13-week old were divided into two groups and fed with normal diet (Group A) and hyperlipidemic diet (Group B) respectively, the latter was subdivided into 7 groups as Group B1 - 7. Besides, a normal control group was set up with C57BL/6J mice. The drugs used for intervention were polydatin (PD, with 26.6 mg/kg as one dose) for detoxifying and Xiongshao Capsule (XC, with 110 mg/kg as one dose) for activating blood circulation respectively. The intervention was started 19 weeks later by treated Group B1 with PD one dose daily, Group B2 with XC one dose daily, Group B3 with PD and XC each 2 doses daily, Group B4 with PD and XC each one dose daily, Group B5 with PD and XC each half dose daily, Group B6 with lovastatin. To the Group B 7 (as a hyperlipidemia model group) as well as Group A and the normal control group, normal saline was given. After 17 weeks of intervention, the expressions of NF-kappaB and MMP-9 in aorta of mice were determined with immunohistochemical assay.


RESULTS
Expressions of NF-kappaB and MMP-9 in aorta and sclerotic plaque were higher in group B7 than those in the normal control group, which were lowered in group B1 - 6 (P < 0.01), and the optimal effect was shown in group B3 (P <0.01).


CONCLUSIONS
Combined use of Chinese herbal medicine for detoxifying and activating blood circulation could reduce expression of NF-kappaB and MMP-9 in aorta of ApoE (-/-) mice, and the effect of the combination of the two was superior to that of use either of them.
Zhang
Jing-chun
JC
Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing. zhangjingchun276@sohu.com
Chen
Ke-ji
KJ
Zheng
Guang-juan
GJ
D000818:Animals; D000924:Anticholesteremic Agents / Q000494:pharmacology; D001011:Aorta / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D001057:Apolipoproteins E / Q000235:genetics*; D001783:Blood Flow Velocity / Q000187:drug effects; D002214:Capsules; D004365:Drugs, Chinese Herbal / Q000494:pharmacology*; D005260:Female; D007150:Immunohistochemistry; D008148:Lovastatin / Q000494:pharmacology; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000096:biosynthesis*; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009131:Muscle, Smooth, Vascular / Q000098:blood supply / Q000187:drug effects / Q000378:metabolism; D016328:NF-kappa B / Q000096:biosynthesis*
D000924:Anticholesteremic Agents; D001057:Apolipoproteins E; D002214:Capsules; D004365:Drugs, Chinese Herbal; D016328:NF-kappa B; C528128:xiongshao; D008148:Lovastatin; D020780:Matrix Metalloproteinase 9